Epidemiology of pulmonary hypertension: New data from the swiss registry

Swiss Medical Weekly

Volumn 138, Issue 25-26, 2008, Pages 379-384

  Tueller, Claudia ^a   Stricker, Hans ^b   Soccal, Paola ^c   Tamm, Michael ^d   Aubert, John David ^e   Maggiorini, Marco ^f   Zwahleng, Marcel ^g   Nicod, Laurent ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Ospedale La Carita   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

Epidemiology; Pulmonary hypertension; Registry

Indexed keywords

ADULT; ARTICLE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; EXERCISE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LUNG DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; PULMONARY HYPERTENSION; REGISTER; WALKING;

EID: 47049091462     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903.
2. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57.
3. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-9.
4. Galie N, Manes A, Uguccioni L, et al. Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest. 1998;114(3 Suppl):184S-94S.
5. Stricker H, Domenighetti G, Popov W, et al. Severe pulmonary hypertension: data from the Swiss Registry. Swiss Med Wkly. 2001;131(23-24):346- 50.
6. Fishman AP. Clinical classification of pulmonary hypertension. Clin Chest Med. 2001;22(3):385-91, vii.
7. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):40S-7S.
8. Die Bevölkerung der Schweiz. In: Bundesamt für Statistik BFS; 2006.
9. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5):343-9.
10. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4):580-7.
11. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30.
12. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161(2 Pt l):487-92.
13. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-8.
14. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-64.
15. McLaughlin W, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-82.
16. Galie N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol. 1995;75(3):55A-62A.
17. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 1996;93(3):484-8.
18. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81.
19. Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas PS. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation. 1989;80(2):353-60.
20. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865-70.
21. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. 2003;108(7):844-8.
22. Voelkel MA, Wynne KM, Badesch DB, Groves BM, Voelkel NF Hyperuricemia in severe pulmonary hypertension. Chest. 2000;117(l):19-24.
23. Cenedese E, Speich R, Dorschner L, et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J. 2006;28(4):808-15.
24. Zagolin BM, Wainstein GE, Uriarte GdCP, Parra RC. Clinical, functional and hemodynamic features of patients with pulmonary arterial hypertension. Rev Med Chil. 2006; 134(5):589-95.
25. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167(5):735-40.
26. Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104-9.